Loyal is a clinical-stage veterinary medicine company developing drugs intended to extend the lifespan and healthspan of dogs. In other words, our mission is to help dogs live longer, healthier lives. We’ve already achieved significant milestones on our path to gaining FDA approval for the first lifespan extension drug for any species. We have three products in our pipeline and expect to bring the first product to market in 2025. Our team includes scientists, veterinarians, engineers, operators, and creatives. Join us in our mission to help dogs everywhere.
External link for Loyal
San Francisco, CA 94103, US
Loyal reposted this
Meet the team behind Loyal! We’re proud of the work we do and have an incredible team making it happen. From vets to scientists to problem solvers, here are a few of the dog lovers bringing our mission to life. → loyal.com/team-spotlight Thanks, Brennen McKenzie, Ashley Tovar, PhD, RD, and Laura Vasquez-Bolanos, PhD, for sharing your love of dogs with us.
Meet the team behind Loyal! We’re proud of the work we do and have an incredible team making it happen. From vets to scientists to problem solvers, here are a few of the dog lovers bringing our mission to life. → loyal.com/team-spotlight Thanks, Brennen McKenzie, Ashley Tovar, PhD, RD, and Laura Vasquez-Bolanos, PhD, for sharing your love of dogs with us.
What do vets think LOY-002's recent FDA progress could mean for patient care? Dr. Brennen McKenzie, our Director of Vet Medicine, spends half of his time in clinical practice, where he sees the limits aging imposes on his patients firsthand. Here’s what Dr. Brennen and other vets have to say about LOY-002’s preliminary efficacy nod (RXE) and its potential to change the way vets practice → loyal.com/rxe-for-vets
It was a big week at Loyal! We're so excited to celebrate our progress towards creating the first-ever FDA-approved longevity drugs for dogs. Here are some highlights: The Washington Post: https://lnkd.in/gK3h6Jy9 dvm360®: https://lnkd.in/gm5k_Htg The Today Show: https://lnkd.in/gBT8nNth The Late Show with Stephen Colbert: https://lnkd.in/gsuJziuE
Good news for senior dogs! 🎉 Our senior dog drug, LOY-002, completed its preliminary FDA efficacy package (RXE). This is a crucial step towards bringing the first longevity drug to dog owners and veterinarians in the next year. What this means: we’re on track to receive FDA conditional approval in late 2025 and launch the first drug developed to give senior dogs more healthy time. A word from our CEO → loyal.com/RXE
"My goal is that every eligible dog is on a longevity drug for them to be healthy longer," said our founder and CEO Celine Halioua to Lisa Bonos of The Washington Post. Today's milestone is an important step towards making an FDA-approved longevity drug a reality this year, and we're thrilled to share our progress. Read the full story: https://lnkd.in/gK3h6Jy9
Heading to WVC 2025? Meet us at Booth 3046 to learn how we’re developing longevity drugs for dogs and try your luck with our scratch tickets for a chance to win a Loyal prize while supplies last. We're also offering multiple CE sessions on canine aging — add them to your calendar now: https://lnkd.in/g5NGJe6s #WVC2025 #VeterinaryMedicine #CanineAging #Longevity
Are you a leader that thrives in a start-up environment, with experience commercializing a small molecule drug product? We're seeking a Senior Director of CMC & DP to oversee all aspects of the commercial manufacturing of our first longevity drug for dogs. Apply here → https://lnkd.in/g-Yxfu_D
“Their lifespans are never long enough.” We couldn’t agree more – and that’s why we’re developing the first longevity drugs for dogs. Hear more from Gabriela Vidal of CBS News Colorado who visited one of our clinical trial sites in Denver to learn more about how we’re working with vets across the country to extend both the quantity and quality of time we get to spend with our favorite four-legged companions: https://lnkd.in/ggq3sddR
Grateful for the chance to reflect, look ahead, and celebrate the amazing work our team is doing during our in-person strategy sessions these past few days. We’re ready for 2025! Thank you, Tara Viswanathan (cofounder and former CEO of Rupa Health) for an empowering chat on scaling a startup.
Loyal Metaweek 2025, featuring Tara Viswanathan